Skip to Main

Sit in on a conversation with BCG pharma leaders as they discuss advancing drug development with new tools, real-world data, digitization, and collaboration across cross-functional teams.

Clemens Möller is a core member of the Health Care, People & Organization, and Public Sector practices at Boston Consulting Group. He leads the firm's work in biopharma R&D globally, and is the firm’s leading global expert in biomedical 3-D printing.

Clemens's work has focused on leading large-scale transformation initiatives with private and public sector clients. He has consulted biopharma companies and government health care agencies on strategy, innovation, operational readiness, process improvement, and organizational change. Clemens also has extensive experience utilizing data, analytics, and digital technology to drive business acceleration and sustainable value.

Before joining BCG in 2008, Clemens worked on identifying antiviral drug targets at Pfizer and investigated chronic kidney disease at Massachusetts General Hospital and Harvard Medical School.

AREAS OF EXPERTISE

EDUCATION

  • PhD, summa cum laude, molecular and cell biology, University of Heidelberg
  • Master‘s degree, Ecole Supérieure de Biotechnologie de Strasbourg (ESBS)

Publications and Videos

" "

Big Changes Are Coming to Pharma Contract Research Organizations

Even in a strong market, CROs are facing some longer-term challenges that could reshape the industry in the next five to ten years.
reviving-agricultural-innovation-rectangle-2-tcm9-239582.jpg

Reviving Agricultural Innovation in Seeds and Crop Protection

The old innovation model at the big agricultural-input companies no longer works. To survive, they must go digital and focus on customer needs.
bcg-publication-2.jpg

Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation

Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation
biopharma-countdown-brexit-2880x1620-tcm9-196496.jpg

Biopharma’s Countdown to Brexit

As the deadline approaches and many details remain unclear, companies are left with no choice but to plan for a hard Brexit in March 2019. Here’s how to get ready.
organization-for-digital-innovation-2880x1620-78624170-tcm9-180939.jpg

Organizing for Digital Innovation

Embracing digital innovation—especially for traditional companies—requires new capabilities, new ways of working, and a transformational mindset.
biomediacl-3-d-printing1694x650-tcm9-88040.jpg

Biomedical 3-D Printing: A Niche Technology or the Next Big Thing?

Like all disruptive innovations, 3-D printing presents both risks and opportunities for incumbents. The time for health care companies to weigh the ramifications for their business is now.